Hims & Hers shares plunged Monday after Novo Nordisk filed a lawsuit and federal regulators called for an investigation into Hims' compounding strategy for GLP-1 drugs.
Why it matters: Novo's legal offensive escalates an ongoing feud as it moves to defend its crown-jewel drug franchise amid price pressure and rising U.S. competition — and puts at risk a Hims business line that's been central to the telehealth company's growth.
Hims & Hers has backed offplans to sell a cheaper copycat version of Novo Nordisk's Wegovy pill after the Department of Health and Human Services asked for an investigation of whether the telehealth brand violated federal law.
Why it matters: The developments underscored continued tension over compounded GLP-1 weight loss drugs and when companies can make customized versions tailored to patients' needs.
Long-running efforts to limit health plans' ability to deny or delay physician-ordered care are on hold again, despite mounting congressional frustrationwith insurers.
Why it matters: By leaving a measure addressing so-called prior authorization reviews out of the bipartisan health package last week, lawmakers may have lost the chance to address a major source of aggravation for patients and doctors before the midterms.
Trillions of dollars in value have been vaporized from global crypto markets since October, plunging an ascendant industry championed by President Trump into a new bout of turmoil.
Why it matters: Crypto joins a growing list of MAGA coalition partners — from Epstein-focused populists to farmers to Latino men — now questioning whether Trump's return to power has delivered what they were promised.
